Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

Blood Adv. 2023 Aug 22;7(16):4514-4517. doi: 10.1182/bloodadvances.2022009135.

Elisa ten Hacken^{1

2}, Shanye Yin^{1

2}, Robert Redd³, María Hernández Sánchez^{4

5}, Kendell Clement⁶, Gabriela Brunsting Hoffmann¹, Fara F Regis¹, Elizabeth Witten¹, Shuqiang Li^{7

8}, Donna Neuberg³, Luca Pinello⁶, Kenneth J Livak^{7

8}, Catherine J Wu^{1

2

8

9}

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Harvard Medical School, Boston, MA.
³ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
⁴ The Institute of Cancer Molecular and Cellular Biology-Cancer Research Center, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain.
⁵ Departament of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, Madrid, Spain.
⁶ Center for Cancer Research, and Center for Computational and Integrative Biology, Molecular Pathology Unit, Massachussetts General Hospital, Boston, MA.
⁷ Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA.
⁸ Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
⁹ Department of Medicine, Brigham and Women's Hospital, Boston, MA.

No abstract available

Publication types